Roche announced it will expand its collaboration with SQZ Biotechnologies into cell therapy development by offering a new upfront investment of up to $125m. The deal also includes clinical, regulatory and sales milestones worth a potential $250m, while development milestones could land the company more than $1 billion. The announcement follows a similar agreement struck between the two companies in August, worth more than $500m in combined incentives, and comes not long after SQZ secured $72m in Series C financing in 2015 from new investors including Everblue, Illumina Ventures and Invus.
Roche announced it will expand its collaboration with SQZ Biotechnologies into cell therapy development by offering a new upfront investment of up to $125m. The deal also includes clinical, regulatory and sales milestones worth a potential $250m, while development milestones could land the company more than $1 billion. The announcement follows a similar agreement struck between the two companies in 2015, worth more than $500m in combined incentives, and comes not long after SQZ secured $72m in Series C financing in August from new investors including Everblue, Illumina Ventures and Invus.